ABUS – arbutus biopharma corporation (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

ABUS

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

2/3

08:00 am

abus

Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts [Seeking Alpha]

Medium Report

Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts [Seeking Alpha]

Report

1/23

05:06 am

abus

Arbutus Biopharma (NASDAQ:ABUS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Medium Report

Arbutus Biopharma (NASDAQ:ABUS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Report

11/14

04:18 pm

abus

Arbutus Biopharma (NASDAQ:ABUS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.

Low Report

Arbutus Biopharma (NASDAQ:ABUS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.